NASDAQ: LQDA
Liquidia Corporation
Healthcare · Medical - Pharmaceuticals
After hours: $85.65(+1.46%) · as of 7:58 PM ET
Market Cap
$7.51B
52w High
$91.10
52w Low
$16.82
P/E
382.69
Volume
1.45M
Outstanding Shares
88.93M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 325.93% over the last year. Revenue grew 1,936.66% over the trailing twelve months. Operating margin moved from -904.4% to 15.81%. Free cash flow grew 138.32% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/S range (63rd percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at 15.81% — continued expansion would be needed to justify the premium. Revenue growth of 1,936.66% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Company profile
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
6
Buy
0
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 11, 2026
Q3 FY26 · EPS est $0.76 · Revenue est $168.48M
View